BRCA1 founder mutations do not contribute to increased risk of gastric cancer in the Polish population

详细信息    查看全文

• 作者：Małgorzata Ławniczak ; Anna Jakubowska…
• 刊名：Hereditary Cancer in Clinical Practice
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：14
• 期：1
• 全文大小：378 KB
• 参考文献：1.Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global Cancer Statistic, 2012. CA Cancer J Clin. 2015;65:87–108.PubMed CrossRef
  2.Chun N, Ford JM. Genetic testing by cancer site: stomach. Cancer J. 2012;18:355–63.PubMed CrossRef
  3.Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, et al. E-cadherin germline mutations in familial gastric cancer. Nature. 1998;392:402–5.PubMed CrossRef
  4.Richards FM, Mc Kee SA, Rajper MH, Cole TR, Evans DG, Jankowski JA, et al. Germeline E-cadherin gene(CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet. 1999;8:607–10.PubMed CrossRef
  5.Jakubowska A, Ławniczak M, Wojnarska B, Cybulski C, Byrski T, Tołoczko-Grabarek A, et al. CDH1 gene mutations do not contribute in hereditary diffuse gastric cancer in Poland. Fam Cancer. 2010;9:605–8.PubMed PubMedCentral CrossRef
  6.Teodorczyk U, Cybulski C, Wokołorczyk D, Jakubowska A, Starzyńska T, Ławniczak M, et al. The risk of gastric cancer in carriers of CHEK2 mutations. Fam Cancer. 2013;12:473–8.PubMed CrossRef
  7.Figer A, Irmin L, Geva R, Flex D, Sulkes J, Sulkes A, et al. The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel. Br J Cancer. 2001;84:478–81.PubMed PubMedCentral CrossRef
  8.The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91:1310–6.CrossRef
  9.Johannsson O, Loman N, Möller T, Kristoffersson U, Borg A, Olsson H. Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers. Eur J Cancer. 1999;35:1248–57.PubMed CrossRef
  10.Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 woman with ovarian cancer. Am J Hum Genet. 2001;68:700–10.PubMed PubMedCentral CrossRef
  11.Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002;94:1365–72.PubMed CrossRef
  12.Bermejo JL, Hemminki K. Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing. Ann Oncol. 2004;15:1834–41.CrossRef
  13.Moran A, O’Hara C, Khan S, Shack L, Woodward E, Maher E, et al. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer. 2012;11:235–42.PubMed CrossRef
  14.Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed. 2005;7:60.PubMed PubMedCentral
  15.Janavičius R. Founder BRCA1/BRCA2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. EPMA J. 2010;1:397–412.PubMed PubMedCentral CrossRef
  16.Górski B, Byrski T, Huzarski T, Jakubowska A, Menkiszak J, Gronwald J, et al. Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet. 2000;66:1963–8.PubMed PubMedCentral CrossRef
  17.Perkowska M, Brozek I, Wysocka B, Haraldsson K, Sandberg T, Johansson U, et al. BRCA1 and BRCA2 mutation analysis in breast-ovarian cancer families from Northeastern Poland. Hum Mutat. 2003;21:553–4.PubMed CrossRef
  18.Ratajska M, Brozek I, Senkus-Konefka E, Jassem J, Stepnowska M, Palomba G, et al. BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland. Oncol Rep. 2008;19:263–8.PubMed
  19.Gaj P, Kluska A, Nowakowska D, Bałabas A, Piątkowska M, Dabrowska M, et al. High frequency of BRCA1 founder mutations in Polish woman with nonfamilial breast cancer. Fam Cancer. 2012;11:623–8.PubMed CrossRef
  20.Szwiec M, Jakubowska A, Górski B, Huzarski T. Tomiczek-Szwiec, Gronwald J, et al. Recurrent mutations of BRCA1 and BRCA2 in Poland: an update. Clin Genet. 2015;87:288–92.PubMed CrossRef
  21.Górski B, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Grzybowska E, et al. A high proportion of founder BRCA1mutations in Polish breast cancer families. Int J Cancer. 2004;110:683–6.PubMed CrossRef
  22.Cybulski C, Górski B, Gronwald J, Huzarski T, Byrski T, Dębniak T, et al. BRCA1 mutations and prostate cancer in Poland. Eur J Cancer Prev. 2008;17:62–6.PubMed CrossRef
  23.Suchy J, Cybulski C, Górski B, Huzarski T, Byrski T, Dębniak T, et al. BRCA1 mutations and colorectal cancer in Poland. Fam Cancer. 2010;9:541–4.PubMed CrossRef
  24.Brozek I, Ochman K, Debniak J, Morzuch L, Ratajska M, Stepnowska M, et al. High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland. Gynecol Oncol. 2008;108:433–7.PubMed CrossRef
  25.Lauren P. The two histological main types of gastric carcinoma: diffuse and so-colled intestinal type carcinoma. An attempt at histo-clinical classification. Acta Path et Microbiol Scandinav. 1965;64:31–49.
  26.Cybulski C, Wokołorczyk D, Kluźniak W, Jakubowska A, Górski B, Gronwald J, et al. An inherited NBN mutation is associated with poor prognosis prostate cancer. Br J Cancer. 2013;108:461–8.PubMed PubMedCentral CrossRef
  27.Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a Kin-cohort study in Ontario. Canada J Natl Cancer Inst. 2006;98:1694–706.PubMed CrossRef
  28.Jakubowska A, Scott R, Menkiszak J, Gronwald J, Byrski T, Huzarski T, et al. A high frequency of BRCA2 gene mutations in Polish families with ovarian and stomach cancer. Eur J Hum Genet. 2003;11:955–8.PubMed CrossRef
  29.Jakubowska A, Nej K, Huzarski T, Scott RJ, Lubiński J. BRCA2 gene mutations in families with aggregations of breast and stomach cancers. Br J Cancer. 2002;87:888–91.PubMed PubMedCentral CrossRef
  30.Thompson D, Easton DF, the Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002;94:1358–65.PubMed CrossRef
  
• 作者单位：Małgorzata Ławniczak (1)
  Anna Jakubowska (2)
  Andrzej Białek (1)
  Jan Lubiński (2)
  Katarzyna Jaworska–Bieniek (2)
  Katarzyna Kaczmarek (2)
  Teresa Starzyńska (1)
  
  1. Department of Gastroenterology, Pomeranian Medical University, Unii Lubelskiej 1, Szczecin, 71-252, Poland
  2. Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Połabska 4, Szczecin, 70-115, Poland
  
• 刊物主题：Oncology; Cancer Research; Human Genetics;
• 出版者：BioMed Central
• ISSN：1897-4287

文摘

Background Gastric cancer (GC) is part of the spectrum of diseases linked to BRCA1 and BRCA2 mutations that increase the risk of breast and ovarian cancer. Data suggesting an increased risk of developing GC among BRCA1 and BRCA2 mutation carriers are based almost exclusively on indirect studies. The objective was to assess in a direct study whether there is a relationship between GC and selected recurrent BRCA1 and BRCA2 mutations in the Polish population.